The accompanying video presentation by Dr Mautner goes over the...

The accompanying video presentation by Dr Mautner goes over the slides however there was a couple of gems in there. DARRT-2 2nd dose cohort is fully recruited and all three active clinical trials will have readouts in 2HCY22. Results for chroma and sofra pre-clinical work will be in there somewhere as well.

One disappointing aspect is the Lupin program is not active and appears to have been shelved until someone shows interest. Hopefully Novartis see value there once they get their drug through to approval.

With all those readouts to come, any CR to come will either be at a much less dilutive price or not taken up enthusiastically at all. I'm hoping there is another announcement this week to go with this presentation for the NOX team to shop around at San Diego for the BIO International Conference next week.